The chemistry-pharmacy giant Bayer announced Thursday a partnership with the German pharmaceutical company Curevac to support it in the development of its vaccine against Covid-19 currently in the last phase of clinical trial.
Read also: Covid: Can we really vaccinate a million people by the end of January?
The two companies "
enter into a collaboration and services agreement (...) to support CureVac in many areas
" including the production and commercialization of a messenger RNA vaccine "
to facilitate the supply of several hundred million doses
“, Indicates Bayer in a press release without mentioning quantified financial commitment.
Based in Tübingen (west), the CureVac laboratory hopes to put on the market this year the vaccine against Covid-19 for which it announced in December to launch the third and final phase of clinical trials.
The European Commission has already signed a contract with this start-up specializing in messenger RNA, for the purchase of 405 million doses.
"
Bayer will bring its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance
," said the statement from the two companies.
Franz-Werner Haas, CEO of CureVac, quoted in the text, says he hopes this alliance will help "
make our CVnCoV vaccine candidate even more quickly available to as many people as possible
."
Read also: CureVac, German nugget looking for an anti-Covid vaccine
CureVac's vaccine candidate can remain stable for at least three months at refrigerator temperature, CEO says when, in their current version, Pfizer / BioNTech vaccine should be stored at -70 degrees and Moderna's at -20 degrees.
